Albumin-based nanoplatforms have emerged as promising solutions to address these therapeutic challenges by exploiting the inherent biocompatibility, biodegradability, extended circulation half-life, and natural tumor-targeting properties of albumin through interactions with gp60 and SPARC receptors that are overexpressed in TNBC tissues. Here, ALB is linked to neoplasm.